DMRA Stock Summary and Trading Ideas (Damora Therapeutics | NASDAQ:DMRA)

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Damora Therapeutics trades on the NASDAQ stock market under the symbol DMRA.

As of June 8, 2026, DMRA stock price declined to $20.91 with 298,900 million shares trading.

DMRA has a beta of 1.04, meaning it tends to be more sensitive to market movements. DMRA has a correlation of 0.02 to the broad based SPY ETF.

DMRA has a market cap of $1.29 billion. This is considered a Small Cap stock.

The top ETF exchange traded funds that DMRA belongs to (by Net Assets): VXF, XBI, FFSM, FHLC, ONEQ.

DMRA support price is $20.03 and resistance is $21.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DMRA shares will trade within this expected range on the day.